University Of California, San Francisco

New at-home tests can simultaneously detect flu and COVID, offering quicker results and aiding in timely treatment decisions.

Movano Health's Q3 update highlights the relaunch of the Evie Ring, progress on FDA 510(k) clearance for the EvieMED Ring, and new business initiatives focused on expanding healthcare partnerships and clinical wearables.

Medistim ASA announces the PATENT study, an open, prospective, multicenter trial evaluating the immediate clinical benefits and long-term prognostic value of intraoperative completion control using transit time flow measurement (TTFM) and high-frequency ultrasound (HFUS) imaging in patients undergoing bypass surgery for Critical Limb Threatening Ischemia (CLTI) below the knee. The study aims to enroll approximately 450 patients across 15 sites in the USA, Europe, and Asia, with enrollment set to begin by the end of 2024.

UCSF's next-gen metagenomic sequencing (mNGS) test, developed over a decade, effectively diagnoses various pathogens, improving care for neurological infections and detecting new pandemic threats. The test analyzes all nucleic acids in a sample, replacing multiple tests with one, and has been successfully used on thousands of patients. It has potential for early pandemic warning and has received FDA breakthrough device designation.

New data presented at SITC 39th Annual Meeting highlights ciforadenant's potential to overcome anti-PD1 resistance in mCRPC, identifying SPP1+ myeloid cells and adenosine signaling as key mechanisms.

Corvus Pharmaceuticals presents data on ciforadenant's potential to overcome anti-PD1 resistance in mCRPC at SITC 39th Annual Meeting. Studies reveal SPP1+ myeloid cells as critical mediators of immunotherapy resistance, with ciforadenant reducing immunosuppression and enhancing anti-PD1 sensitivity in a murine model. The adenosine gene signature, reflecting adenosine-induced immunosuppression, was elevated in SPP1+ macrophages, supporting ciforadenant's role in shifting to a less immunosuppressive myeloid environment.

Corvus Pharmaceuticals presents data on ciforadenant's potential to overcome anti-PD1 resistance in mCRPC, identifying SPP1+ myeloid cells and adenosine signaling as key mechanisms. The study, led by Dr. Lawrence Fong, showed ciforadenant's efficacy in reducing immunosuppression and enhancing anti-PD1 therapy sensitivity in a murine model, consistent with clinical trial data.

John Sims presented at CTAD that starting donanemab at low doses and titrating up reduced ARIA-E by 40%, especially for APOE homozygotes. Gil Rabinovici's new donanemab AUR emphasize stricter MRI criteria for safety. Lilly plans to submit data to update the label.

Researchers debate replacing cognitive tests with blood tests and brain scans for early Alzheimer’s diagnosis, with proponents arguing biomarkers detect the disease at its earliest, treatable stage, while critics warn of potential distress and misdiagnosis for asymptomatic individuals.

Movano Health tested its new blood pressure wrist wearable during a hypoxia clinical trial at UCSF, featuring 12 mmWave antennas and a custom IC for enhanced data collection. The device also monitors pulse rate, blood oxygen saturation, respiration rate, and ECG waveforms.